Role of the growth hormone–IGF-1 axis in cancer

References

• Nilsson A, Carlsson B, Isgaard J, Isaksson OG, Rymo L. Regulation by GH of insulin-like growth factor-I mRNA expression in rat epiphyseal growth plate as studied with in situ hybridization. J. Endocrinol.125(1), 67–74 (1990).
   PubMed Web of Science ®Google Scholar
• Yakar S, Liu JL, Stannard B et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl Acad. Sci. USA96(13), 7324–7329 (1999).
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin. Endocrinol. (Oxf.)64(2), 115–121 (2006).
   PubMedGoogle Scholar
• Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev.28(1), 20–47 (2007).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Harrela M, Koistinen H, Kaprio J et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J. Clin. Invest.98(11), 2612–2615 (1996).
   PubMed Web of Science ®Google Scholar
• Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Horm. IGF Res.10(Suppl. B), S21–S24 (2000).
   Google Scholar
• Laban C, Bustin SA, Jenkins PJ. The GH–IGF-I axis and breast cancer. Trends Endocrinol. Metab.14(1), 28–34 (2003).
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Ueki K, Tobe K et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature390(6655), 91–96 (1997).
   PubMed Web of Science ®Google Scholar
• Frank SJ. Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling. J. Mammary Gland Biol. Neoplasia.13(1), 119–129 (2008).
   PubMedGoogle Scholar
• Brooks AJ, Wooh JW, Tunny KA, Waters MJ. Growth hormone receptor; mechanism of action. Int. J. Biochem. Cell Biol.40(10), 1984–1989 (2008).
   PubMed Web of Science ®Google Scholar
• Gunnell D, Okasha M, Smith GD, Oliver SE, Sandhu J, Holly JM. Height, leg length, and cancer risk: a systematic review. Epidemiol. Rev.23(2), 313–342 (2001).
   PubMed Web of Science ®Google Scholar
• Queiroga FL, Perez-Alenza D, Silvan G, Pena L, Lopes CS, Illera JC. Serum and intratumoural GH and IGF-I concentrations: Prognostic factors in the outcome of canine mammary cancer. Res. Vet. Sci.89(3), 396-403 (2010).
   PubMedGoogle Scholar
• Lundqvist E, Kaprio J, Verkasalo PK et al. Co-twin control and cohort analyses of body mass index and height in relation to breast, prostate, ovarian, corpus uteri, colon and rectal cancer among Swedish and Finnish twins. Int. J. Cancer121(4), 810–818 (2007).
   PubMedGoogle Scholar
• Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol.11(6), 530–542 (2010).
   PubMed Web of Science ®Google Scholar
• Peyrat JP, Bonneterre J, Hecquet B et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer29A(4), 492–497 (1993).
   PubMed Web of Science ®Google Scholar
• Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol. Pathol.54(3), 149–154 (2001).
   PubMedGoogle Scholar
• Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res.60(14), 3744–3748 (2000).
   PubMed Web of Science ®Google Scholar
• Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr. Rev.30(1), 51–74 (2009).
   PubMed Web of Science ®Google Scholar
• Rudd MF, Webb EL, Matakidou A et al. Variants in the GH–IGF axis confer susceptibility to lung cancer. Genome Res.16(6), 693–701 (2006).
   PubMed Web of Science ®Google Scholar
• Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J. Natl Cancer Inst.94(6), 454–460 (2002).
   PubMedGoogle Scholar
• Menashe I, Maeder D, Garcia-Closas M et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res.70(11), 4453–4459 (2010).
   PubMed Web of Science ®Google Scholar
• Canzian F, McKay JD, Cleveland RJ et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol. Biomarkers Prev.14(10), 2316–2325 (2005).
   PubMedGoogle Scholar
• Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol. Biomarkers Prev.17(4), 880–888 (2008).
   PubMed Web of Science ®Google Scholar
• Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol. Biomarkers Prev.13(4), 573–582 (2004).
   PubMed Web of Science ®Google Scholar
• Verheus M, Maskarinec G, Woolcott CG et al. IGF1, IGFBP1, and IGFBP3 genes and mammographic density: the Multiethnic Cohort. Int. J. Cancer127(5), 1115–1123 (2010).
   PubMedGoogle Scholar
• Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev.14(5), 1204–1211 (2005).
   PubMedGoogle Scholar
• Friedrichsen DM, Hawley S, Shu J et al.IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate65(1), 44–51 (2005).
   PubMedGoogle Scholar
• Park K, Kim JH, Jeon HG, Byun SS, Lee E. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urology75(6), 1516, e1–e7 (2010).
   PubMedGoogle Scholar
• Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int. J. Cancer124(10), 2416–2429 (2009).
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Cleveland R, Norat T et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int. J. Cancer126(7), 1702–1715 (2010).
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Meyerhardt JA, Chan AT et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol.27(2), 176–185 (2009).
   PubMed Web of Science ®Google Scholar
• Stattin P, Bylund A, Rinaldi S et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J. Natl Cancer Inst.92(23), 1910–1917 (2000).
   PubMed Web of Science ®Google Scholar
• Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract. Res. Clin. Endocrinol. Metab.22(4), 639–657 (2008).
   PubMed Web of Science ®Google Scholar
• Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev. Endocr. Metab. Disord.9(1), 41–58 (2008).
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS et al. The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. J. Clin. Endocrinol. Metab.92(10), 3854–3860 (2007).
   PubMed Web of Science ®Google Scholar
• Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm. IGF Res.17(1), 54–57 (2007).
   PubMed Web of Science ®Google Scholar
• Chernausek SD. Growth and development: how safe is growth hormone therapy for children? Nat. Rev. Endocrinol.6(5), 251–253 (2010).
   PubMedGoogle Scholar
• Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J. Clin. Endocrinol. Metab.95(1), 167–177 (2010).
   PubMed Web of Science ®Google Scholar
• Ergun-Longmire B, Mertens AC, Mitby P et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol. Metab.91(9), 3494–3498 (2006).
   PubMed Web of Science ®Google Scholar
• Luft R, Olivecrona H. Hypophysectomy in the treatment of malignant tumors. Cancer10(4), 789–794 (1957).
   PubMedGoogle Scholar
• Moon HD, Simpson ME, Li CH, Evans HM. Neoplasms in rats treated with pituitary growth hormone; pulmonary and lymphatic tissues. Cancer Res.10(5), 297–308 (1950).
   PubMed Web of Science ®Google Scholar
• Tornell J, Carlsson B, Pohjanen P, Wennbo H, Rymo L, Isaksson O. High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J. Steroid Biochem. Mol. Biol.43(1–3), 237–242 (1992).
   PubMedGoogle Scholar
• Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer72(5), 1189–1193 (1995).
   PubMed Web of Science ®Google Scholar
• Snibson KJ, Bhathal PS, Adams TE. Overexpressed growth hormone (GH) synergistically promotes carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice. Liver21(2), 149–158 (2001).
   PubMedGoogle Scholar
• Miquet JG, Gonzalez L, Matos MN et al. Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation. J. Endocrinol.198(2), 317–330 (2008).
   PubMedGoogle Scholar
• Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R, Rosen JM. Cooperative interaction between mutant p53 and des(1–3)IGF-I accelerates mammary tumorigenesis. Oncogene19(7), 889–898 (2000).
   PubMed Web of Science ®Google Scholar
• Carboni JM, Lee AV, Hadsell DL et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res.65(9), 3781–3787 (2005).
   PubMed Web of Science ®Google Scholar
• Michaylira CZ, Simmons JG, Ramocki NM et al. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo. Am. J. Physiol. Gastrointest. Liver Physiol.291(3), G472–G481 (2006).
   Google Scholar
• Ikeno Y, Hubbard GB, Lee S et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J. Gerontol. A Biol. Sci. Med. Sci.64(5), 522–529 (2009).
   PubMedGoogle Scholar
• Zhang X, Mehta RG, Lantvit DD et al. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis28(1), 143–150 (2007).
   PubMed Web of Science ®Google Scholar
• Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res.56(7), 1509–1511 (1996).
   PubMed Web of Science ®Google Scholar
• Thordarson G, Semaan S, Low C et al. Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Res. Treat.87(3), 277–290 (2004).
   PubMed Web of Science ®Google Scholar
• Shen Q, Lantvit DD, Lin Q et al. Advanced rat mammary cancers are growth hormone dependent. Endocrinology148(10), 4536–4544 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Z, Prins GS, Coschigano KT et al. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology146(12), 5188–5196 (2005).
   PubMed Web of Science ®Google Scholar
• Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br. J. Cancer85(3), 428–430 (2001).
   PubMed Web of Science ®Google Scholar
• Divisova J, Kuiatse I, Lazard Z et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res. Treat.98(3), 315–327 (2006).
   PubMed Web of Science ®Google Scholar
• McCutcheon IE, Flyvbjerg A, Hill H et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J. Neurosurg.94(3), 487–492 (2001).
   PubMed Web of Science ®Google Scholar
• Dagnaes-Hansen F, Duan H, Rasmussen LM, Friend KE, Flyvbjerg A. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res.24(6), 3735–3742 (2004).
   PubMed Web of Science ®Google Scholar
• de Ostrovich KK, Lambertz I, Colby JK et al. Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am. J. Pathol.173(3), 824–834 (2008).
   PubMedGoogle Scholar
• Olivo-Marston SE, Hursting SD, Lavigne J et al. Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol. Carcinog.48(12), 1071–1076 (2009).
   PubMedGoogle Scholar
• Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res.62(4), 1030–1035 (2002).
   PubMed Web of Science ®Google Scholar
• Wu Y, Cui K, Miyoshi K et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res.63(15), 4384–4388 (2003).
   PubMed Web of Science ®Google Scholar
• Waters MJ. The growth hormone receptor. In: The Handbook of Physiology. Kostyo JL, Goodman HM (Eds). Oxford University Press, NY, USA, 397–444 (1999).
   Google Scholar
• Gebre-Medhin M, Kindblom LG, Wennbo H, Tornell J, Meis-Kindblom JM. Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol.158(4), 1217–1222 (2001).
   PubMed Web of Science ®Google Scholar
• Lin CJ, Mendonca BB, Lucon AM, Guazzelli IC, Nicolau W, Villares SM. Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues – an analysis by quantitative polymerase chain reaction technique. J. Clin. Endocrinol. Metab.82(8), 2671–2676 (1997).
   PubMedGoogle Scholar
• Wu X, Liu F, Yao X, Li W, Chen C. Growth hormone receptor expression is up-regulated during tumorigenesis of human colorectal cancer. J. Surg. Res.143(2), 294–299 (2007).
   PubMedGoogle Scholar
• Harrison SM, Barnard R, Ho KY, Rajkovic I, Waters MJ. Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full-length GH receptor. Endocrinology136(2), 651–659 (1995).
   PubMedGoogle Scholar
• Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I et al. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer. Eur. J. Endocrinol.156(2), 187–194 (2007).
   PubMedGoogle Scholar
• Lincoln DT, Sinowatz F, Kolle S, Takahashi H, Parsons P, Waters M. Up-regulation of growth hormone receptor immunoreactivity in human melanoma. Anticancer Res.19(3A), 1919–1931 (1999).
   PubMed Web of Science ®Google Scholar
• Weiss-Messer E, Merom O, Adi A et al. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol. Cell Endocrinol.220(1–2), 109–123 (2004).
   PubMedGoogle Scholar
• Mol JA, van Garderen E, Selman PJ, Wolfswinkel J, Rijinberk A, Rutteman GR. Growth hormone mRNA in mammary gland tumors of dogs and cats. J. Clin. Invest.95(5), 2028–2034 (1995).
   PubMed Web of Science ®Google Scholar
• Mol JA, Henzen-Logmans SC, Hageman P, Misdorp W, Blankenstein MA, Rijnberk A. Expression of the gene encoding growth hormone in the human mammary gland. J. Clin. Endocrinol. Metab.80(10), 3094–3096 (1995).
   PubMed Web of Science ®Google Scholar
• Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes CS, Illera JC. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17β-estradiol) in canine mammary tumours. J. Steroid Biochem. Mol. Biol.110(1–2), 76–82 (2008).
   PubMedGoogle Scholar
• Raccurt M, Lobie PE, Moudilou E et al. High stromal and epithelial human GH gene expression is associated with proliferative disorders of the mammary gland. J. Endocrinol.175(2), 307–318 (2002).
   PubMed Web of Science ®Google Scholar
• Ratkaj I, Stajduhar E, Vucinic S et al. Integrated gene networks in breast cancer development. Funct. Integr. Genomics10(1), 11–19 (2010).
   PubMedGoogle Scholar
• van Garderen E, Schalken JA. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol. Cell Endocrinol.197(1–2), 153–165 (2002).
   PubMedGoogle Scholar
• Gil-Puig C, Blanco M, Garcia-Caballero T, Segura C, Perez-Fernandez R. Pit-1/GHF-1 and GH expression in the MCF-7 human breast adenocarcinoma cell line. J. Endocrinol.173(1), 161–167 (2002).
   PubMedGoogle Scholar
• Chopin LK, Veveris-Lowe TL, Philipps AF, Herington AC. Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm. IGF Res.12(2), 126–136 (2002).
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Spiezia S et al. Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J. Clin. Endocrinol. Metab.85(10), 3754–3761 (2000).
   PubMedGoogle Scholar
• Colao A, Di Somma C, Spiezia S, Filippella M, Pivonello R, Lombardi G. Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. J. Clin. Endocrinol. Metab.88(1), 88–94 (2003).
   PubMed Web of Science ®Google Scholar
• Wang W, Edington HD, Rao UN et al. Effects of high-dose IFNα2β on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin. Cancer Res.14(24), 8314–8320 (2008).
   PubMedGoogle Scholar
• Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology140(5), 1984–1989 (1999).
   PubMed Web of Science ®Google Scholar
• Cunningham BC, Bass S, Fuh G, Wells JA. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science250(4988), 1709–1712 (1990).
   PubMed Web of Science ®Google Scholar
• Zhu T, Starling-Emerald B, Zhang X et al. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res.65(1), 317–324 (2005).
   PubMedGoogle Scholar
• Xu XQ, Emerald BS, Goh EL et al. Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. J. Biol. Chem.280(25), 23987–24003 (2005).
   PubMed Web of Science ®Google Scholar
• Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE. The contribution of growth hormone to mammary neoplasia. J. Mammary Gland Biol. Neoplasia.13(1), 131–145 (2008).
   PubMedGoogle Scholar
• Brunet-Dunand SE, Vouyovitch C, Araneda S et al. Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology150(3), 1341–1352 (2009).
   PubMed Web of Science ®Google Scholar
• Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology142(2), 767–777 (2001).
   PubMedGoogle Scholar
• van den Eijnden MJ, Strous GJ. Autocrine growth hormone: effects on growth hormone receptor trafficking and signaling. Mol. Endocrinol.21(11), 2832–2846 (2007).
   PubMedGoogle Scholar
• Conway-Campbell BL, Wooh JW, Brooks AJ et al. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc. Natl Acad. Sci. USA104(33), 13331–13336 (2007).
   PubMed Web of Science ®Google Scholar
• Mertani HC, Garcia-Caballero T, Lambert A et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer79(2), 202–211 (1998).
   PubMed Web of Science ®Google Scholar
• Lincoln DT, Kaiser HE, Raju GP, Waters MJ. Growth hormone and colorectal carcinoma: localization of receptors. In Vivo14(1), 41–49 (2000).
   PubMedGoogle Scholar
• Garcia-Caballero T, Mertani HM, Lambert A et al. Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas. Endocrine12(3), 265–271 (2000).
   PubMedGoogle Scholar
• Dehari R, Nakamura Y, Okamoto N, Nakayama H. Increased nuclear expression of growth hormone receptor in uterine cervical neoplasms of women under 40 years old. Tohoku J. Exp. Med.216(2), 165–172 (2008).
   PubMedGoogle Scholar
• Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Cancer94(2), 184–188 (2006).
   PubMed Web of Science ®Google Scholar
• Conway-Campbell BL, Brooks AJ, Robinson PJ, Perani M, Waters MJ. The extracellular domain of the growth hormone receptor interacts with coactivator activator to promote cell proliferation. Mol. Endocrinol.22(9), 2190–2202 (2008).
   PubMedGoogle Scholar
• Sui Y, Yang Z, Xiong S et al. Gene amplification and associated loss of 5´ regulatory sequences of CoAA in human cancers. Oncogene26(6), 822–835 (2007).
   PubMedGoogle Scholar
• Li X, Hoeppner LH, Jensen ED, Gopalakrishnan R, Westendorf JJ. Co-activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors. J. Cell. Biochem.108(2), 378–387 (2009).
   PubMedGoogle Scholar
• Auboeuf D, Dowhan DH, Li X et al. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol. Cell Biol.24(1), 442–453 (2004).
   PubMed Web of Science ®Google Scholar
• Carver KC, Schuler LA. Prolactin does not require insulin-like growth factor intermediates but synergizes with insulin-like growth factor I in human breast cancer cells. Mol. Cancer Res.6(4), 634–643 (2008).
   PubMedGoogle Scholar
• Carver KC, Arendt LM, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol. Cell Endocrinol.307(1–2), 1–7 (2009).
   PubMedGoogle Scholar
• Tornell J, Rymo L, Isaksson OG. Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. Int. J. Cancer49(1), 114–117 (1991).
   PubMedGoogle Scholar
• Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest.100(11), 2744–2751 (1997).
   PubMed Web of Science ®Google Scholar
• Clevenger CV. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis.18, 75–86 (2003).
   PubMedGoogle Scholar
• Dagvadorj A, Collins S, Jomain JB et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology148(7), 3089–3101 (2007).
   PubMed Web of Science ®Google Scholar
• Rouet V, Bogorad RL, Kayser C et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc. Natl Acad. Sci. USA107(34), 15199–15204 (2010).
   PubMed Web of Science ®Google Scholar
• Harbaum L, Pollheimer MJ, Bauernhofer T et al. Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases. Mod. Pathol.23(7), 961–971 (2010).
   PubMed Web of Science ®Google Scholar
• Mohankumar KM, Perry JK, Kannan N et al. Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology149(5), 2219–2229 (2008).
   PubMedGoogle Scholar
• Tang JZ, Zuo ZH, Kong XJ et al. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology151(1), 43–55 (2010).
   PubMedGoogle Scholar
• Tang JZ, Kong XJ, Banerjee A et al. STAT3a is oncogenic for endometrial carcinoma cells and mediates the oncogenic effects of autocrine human growth hormone. Endocrinology151(9), 4133–4145 (2010).
   PubMed Web of Science ®Google Scholar
• Levine RL, Gilliland DG. JAK-2 mutations and their relevance to myeloproliferative disease. Curr. Opin Hematol.14(1), 43–47 (2007).
   PubMed Web of Science ®Google Scholar
• Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu. Rev. Med.59, 213–222 (2008).
   PubMed Web of Science ®Google Scholar
• Lacronique V, Boureux A, Valle VD et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science278(5341), 1309–1312 (1997).
   PubMed Web of Science ®Google Scholar
• Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med.183(3), 811–820 (1996).
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med.3(7), e270 (2006).
   PubMed Web of Science ®Google Scholar
• Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J. Biol. Chem.285(8), 5296–5307 (2010).
   PubMed Web of Science ®Google Scholar
• Hoelbl A, Schuster C, Kovacic B et al. STAT5 is indispensable for the maintenance of Bcr/Abl-positive leukaemia. EMBO Mol. Med.2(3), 98–110 (2010).
   PubMed Web of Science ®Google Scholar
• Schwaller J, Parganas E, Wang D et al. STAT5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell6(3), 693–704 (2000).
   PubMed Web of Science ®Google Scholar
• Gu L, Vogiatzi P, Puhr M et al. STAT5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr. Relat. Cancer17(2), 481–493 (2010).
   PubMedGoogle Scholar
• Mirmohammadsadegh A, Hassan M, Bardenheuer W et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through Srs and Jak1 kinases. J. Invest. Dermatol.126(10), 2272–2280 (2006).
   PubMed Web of Science ®Google Scholar
• Hassel JC, Winnemoller D, Schartl M, Wellbrock C. STAT5 contributes to antiapoptosis in melanoma. Melanoma Res.18(6), 378–385 (2008).
   PubMedGoogle Scholar
• Lee TK, Man K, Poon RT et al. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res.66(20), 9948–9956 (2006).
   PubMedGoogle Scholar
• Wagner KU, Rui H. Jak2/STAT5 signaling in mammogenesis, breast cancer initiation and progression. J. Mammary Gland Biol. Neoplasia.13(1), 93–103 (2008).
   PubMedGoogle Scholar
• Koppikar P, Lui VW, Man D et al. Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial–mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin. Cancer Res.14(23), 7682–7690 (2008).
   PubMedGoogle Scholar
• Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr. Opin Cell Biol.20(2), 150–155 (2008).
   PubMedGoogle Scholar
• Mallette FA, Gaumont-Leclerc MF, Huot G, Ferbeyre G. Myc down-regulation as a mechanism to activate the Rb pathway in STAT5a-induced senescence. J. Biol. Chem.282(48), 34938–34944 (2007).
   PubMed Web of Science ®Google Scholar
• Mallette FA, Moiseeva O, Calabrese V, Mao B, Gaumont-Leclerc MF, Ferbeyre G. Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence. Ann. NY Acad. Sci.1197, 142–151 (2010).
   PubMedGoogle Scholar
• Schartl M, Wilde B, Laisney JA, Taniguchi Y, Takeda S, Meierjohann S. A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies. J. Invest. Dermatol.130(1), 249–258 (2010).
   PubMed Web of Science ®Google Scholar
• Mohapatra S, Coppola D, Riker AI, Pledger WJ. Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma. Mol. Cancer Res.5(2), 145–151 (2007).
   PubMedGoogle Scholar
• Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene22(42), 6609–6620 (2003).
   PubMed Web of Science ®Google Scholar
• Mohapatra S, Chu B, Wei S et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res.63(23), 8523–8530 (2003).
   PubMedGoogle Scholar
• Ahonen TJ, Xie J, LeBaron MJ et al. Inhibition of transcription factor STAT5 induces cell death of human prostate cancer cells. J. Biol. Chem.278(29), 27287–27292 (2003).
   PubMed Web of Science ®Google Scholar
• Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin. Cancer Res.14(5), 1317–1324 (2008).
   PubMed Web of Science ®Google Scholar
• Kazansky AV, Spencer DM, Greenberg NM. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res.63(24), 8757–8762 (2003).
   PubMedGoogle Scholar
• Ginestier C, Wicha MS. Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res.9(4), 109 (2007).
   PubMedGoogle Scholar
• Tan SH, Dagvadorj A, Shen F et al. Transcription factor STAT5 synergizes with androgen receptor in prostate cancer cells. Cancer Res.68(1), 236–248 (2008).
   PubMed Web of Science ®Google Scholar
• Yamashita H, Iwase H, Toyama T, Fujii Y. Naturally occurring dominant-negative STAT5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene22(11), 1638–1652 (2003).
   PubMedGoogle Scholar
• Iavnilovitch E, Groner B, Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol. Cancer Res.1(1), 32–47 (2002).
   PubMed Web of Science ®Google Scholar
• Iavnilovitch E, Cardiff RD, Groner B, Barash I. Deregulation of STAT5 expression and activation causes mammary tumors in transgenic mice. Int. J. Cancer112(4), 607–619 (2004).
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood108(10), 3472–3476 (2006).
   PubMed Web of Science ®Google Scholar
• Ding J, Komatsu H, Wakita A et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood103(11), 4198–4200 (2004).
   PubMed Web of Science ®Google Scholar
• Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J. Endocrinol.206(1), 1–11 (2010).
   PubMed Web of Science ®Google Scholar
• Lempereur L, Brambilla D, Scoto GM et al. Growth hormone protects human lymphocytes from irradiation-induced cell death. Br. J. Pharmacol.138(8), 1411–1416 (2003).
   PubMedGoogle Scholar
• Wu X, Wan M, Li G et al. Growth hormone receptor overexpression predicts response of rectal cancers to pre-operative radiotherapy. Eur. J. Cancer42(7), 888–894 (2006).
   PubMedGoogle Scholar
• Zatelli MC, Minoia M, Mole D et al. Growth hormone excess promotes breast cancer chemoresistance. J. Clin. Endocrinol. Metab.94(10), 3931–3938 (2009).
   PubMedGoogle Scholar
• Blackmore DG, Golmohammadi MG, Large B, Waters MJ, Rietze RL. Exercise increases neural stem cell number in a growth hormone-dependent manner, augmenting the regenerative response in aged mice. Stem Cells27(8), 2044–2052 (2009).
   PubMedGoogle Scholar